Bleeding disorders (preventing and controlling&nbsp;bleeding from small blood vessels haemorrhage menorrhagia, neonatal intraventricular and periventricular haemorrhages).

Medicinal Benefits:

Styptovit-E Tablet contains Etamsylate, a hemostatic agent that improves platelet adhesion by restoring capillary resistance and improving platelet adhesion. On the other hand, Styptovit-E Tablet also inhibits the biosynthesis and action of the prostaglandin. These effects help to decrease abnormal bleeding. Thus it treats, controls, and improves various disease conditions and symptoms.

FAQs

How does Styptovit-E Tablet work?

Etamsylate, a hemostatic substance found in Styptovit-E Tablet , works by restoring capillary resistance and enhancing platelet adhesion. On the other hand, Styptovit-E Tablet also inhibits the biosynthesis and action of the prostaglandin. These effects help to decrease abnormal bleeding.

Are there any specific contraindication associated with Styptovit-E Tablet ?

Yes, Styptovit-E Tablet is contraindicated in people with known allergies to any of the components of this medicine. It should be avoided in people with porphyria (a group of rare inherited blood disorders).

What should I do if I miss a dose of Styptovit-E Tablet ?

In case you have missed a dose, skip the missed dose. Then resume your next dose as normal. Do not take a double dose in any case.

Can I stop using Styptovit-E Tablet on my own?

No, you are not recommended to stop using Styptovit-E Tablet without consulting your doctor, as it may cause recurring bleeding. Therefore, take Styptovit-E Tablet for as long as your doctor has prescribed it, and if you are experiencing any difficulty while taking Styptovit-E Tablet , please consult your doctor.

In which conditions is Styptovit-E Tablet prescribed?

Majority of cases, Styptovit-E Tablet is prescribed by your doctor for prevention and control of bleeding from small blood vessels haemorrhage menorrhagia and neonatal intraventricular haemorrhage. Besides this, it can also be used to prevent periventricular haemorrhages in prematurely born children.